Martin Metzenmacher

MET Expression in Advanced Non–Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy

Henning Reis, Martin Metzenmacher, Moritz Goetz et al. · Clinical Lung Cancer · 2018 · 106 citations

Met Expression, Medicine, Metronomic Therapy +8

KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

Martin Sebastian, Wilfried Eberhardt, Petra Hoffknecht et al. · Lung Cancer · 2021 · 75 citations · Full text

Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer – does it change therapeutic decisions in comparison to 18F-FDG PET/CT?

Benedikt M. Schaarschmidt, Johannes Grueneisen, Martin Metzenmacher et al. · European Radiology · 2016 · 64 citations

Positron Emission Tomography, 18F-fdg Pet/ct, Oncologic Imaging +12

Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer

Marcel Wiesweg, Stefan Kasper, Karl Worm et al. · Oncogene · 2018 · 57 citations

Medicine, Pathology, Colorectal Cancer +7

Machine learning reveals a PD-L1–independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context

Marcel Wiesweg, Fabian Mairinger, Henning Reis et al. · European Journal of Cancer · 2020 · 53 citations

Systems Biology, Engineering, Machine Learning +11